A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4 Itovebi is the first PI3K-targeted therapy to ...

These medications can target the pathways of: Vascular endothelial growth factor (VEGF): A signaling protein that stimulates the ... and migration that can contribute to progression of some cancers ...

Radiation therapy can promote the epidermal growth factor receptor (EGFR) ligand amphiregulin, which increases growth of ...

Oncology, a team of expert scientists specializing in immuno-oncology extensively outlined the complexities involved in the ...

Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized ...

The anti-aging conversation is shifting from surface fixes to science-backed renewal. Discover how growth factors (proteins ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

DelveInsight’s Breast Cancer pipeline report depicts a robust space with 100+ Breast Cancer companies working to develop 120+ pipeline therapies for Breast Cancer treatment.

FuelCell Energy builds and delivers firm, clean, energy through high-efficiency fuel cell platforms, which can help data centers meet today’s energy and climate goals without disruption, downtime in a ...